Search results
Showing 76 to 90 of 120 results for multiple sclerosis
This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS54Show all sections
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
This advice has been updated and replaced by NICE guideline NG220.
This guidance has been updated and replaced by NICE guideline NG220.
Evobrutinib for treating relapsing multiple sclerosis [ID6313]
In development [GID-TA11357] Expected publication date: TBC
Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)
This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s advice on daclizumab.
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)
This guidance has been updated and replaced by NICE technology appraisal guidance 616.
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)
Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.
This guidance has been updated and replaced by NICE interventional procedures guidance 640.
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)
This guidance has been updated and replaced by NICE technology appraisal guidance 527.
This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
CG170/4 | Are comprehensive early interventions that combine multiple elements and are delivered by parents and teachers (for example,...